about
Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsAntiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirusValganciclovir results in improved oral absorption of ganciclovir in liver transplant recipientsSusceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovirInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activityAlkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitroCytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplantsLeflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation.Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions.Detailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCRA model of human cytomegalovirus infection in severe combined immunodeficient mice.Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Successful management of multifactorial colitis in a recipient of hematopoietic stem cell transplant: a case report.Impact of sequence variation in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cellsInhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.The search for new therapies for human cytomegalovirus infections.Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.Human cytomegalovirus UL50 and UL53 recruit viral protein kinase UL97, not protein kinase C, for disruption of nuclear lamina and nuclear egress in infected cellsSequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity.Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.Characterization of the human herpesvirus 6 U69 gene product and identification of its nuclear localization signal.Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients
P2860
Q24537618-9FC03B07-3584-4B3D-B5AC-85F634B8C4B1Q28069489-3C2755ED-1373-4804-BE31-20BEB961A117Q28079823-C237BFB2-F0B7-4178-AAFD-D4B1C56D7845Q28344048-BCDF8F76-FC1F-4207-B2E8-AE3C43DEC551Q28344757-B8090D87-5F9A-4F7C-85EB-F897EE7467C5Q28353356-6C226321-A3BC-45AE-B293-B2A25E6BE365Q28362995-65B00FDB-2E28-4601-9AF0-F4854E6B6EBDQ31011523-307F49C4-097A-482C-B204-787487FBCFA0Q33522300-6FFD35E6-679A-440E-B897-EE62C81327FFQ33592427-81C51730-FE96-4CEA-A07E-0AF4F996AC16Q33935329-4DE7D6E6-2EF5-45D9-BD75-8B84C1F05A0BQ34073558-6660E754-6FF7-4B2F-8FE7-7C3BE3D7C96EQ34111307-74E49B20-26DB-4A14-A0A3-68BB58A2037CQ34111476-FEC9D388-D471-421F-A0D6-0C07B55268BAQ34670354-8D46E069-807D-4BF9-A729-90CB208A4FF5Q34922240-0D107AA5-FC81-497D-945D-535BD245BA05Q35036076-7C684179-75F3-4E3D-98A7-A4AD44A6C552Q35103227-84347697-0548-44C0-9EA3-8B707B5964A1Q35558815-64E6AB79-87B9-4BE2-B23E-01CA11E9B89EQ35573953-9CED1595-7C24-46DA-AAC4-E1EDBA81CD57Q35692301-0B397E33-AA96-4F98-9203-BD2A05F8DC78Q35943427-E690E860-07B5-4A90-9A7E-0AC4E13E903EQ36124353-E6ABE172-61FD-4D16-B02F-A7C962E17E3CQ36177655-0CBB41B2-9A6C-4D77-BF5E-4B882AC0B69BQ36944070-1ED28496-19C2-4B54-A402-4970AF8F46BBQ37173390-08B56A4B-F925-4A6C-AC83-2807849CA644Q37202971-4AC59DAC-E226-4CE7-B697-454DB096A80CQ37252891-EA6F315C-31DF-4ECE-ABDD-B2865032052DQ37568962-FC6D1C41-9D96-4192-A488-3DBF03415777Q37734486-4422ACD7-BC88-4424-AFAA-70DFD9AF6C26Q37811458-93842245-088F-46EC-8920-706F3C02426CQ39025231-EDA1382F-156A-4348-87B5-30D0DFD8FD17Q39071752-1BAF23AE-7008-4675-81D2-B707ADFA220FQ39478485-B9CB06C0-4705-4C43-A9A3-82943D6BF852Q39479368-098ACAE6-74FB-4A9F-8C34-C74D7DB99DCDQ39585516-A097F463-B1E1-4CBC-8309-63F6BF11199DQ39626863-6941438C-B5A1-4056-A9DB-83784F1C6914Q40051825-7489A79D-5EA8-4135-89A5-63ECB6C84973Q40289512-3EFD37E2-A0D5-4DF2-8CB7-A32D16AF9788Q40570063-5C3274AE-DA11-46C7-9DCC-C2341AAEE12A
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Resistance of human cytomegalovirus to antiviral drugs.
@ast
Resistance of human cytomegalovirus to antiviral drugs.
@en
Resistance of human cytomegalovirus to antiviral drugs.
@nl
type
label
Resistance of human cytomegalovirus to antiviral drugs.
@ast
Resistance of human cytomegalovirus to antiviral drugs.
@en
Resistance of human cytomegalovirus to antiviral drugs.
@nl
prefLabel
Resistance of human cytomegalovirus to antiviral drugs.
@ast
Resistance of human cytomegalovirus to antiviral drugs.
@en
Resistance of human cytomegalovirus to antiviral drugs.
@nl
P2860
P1476
Resistance of human cytomegalovirus to antiviral drugs.
@en
P2093
P2860
P304
P407
P577
1999-04-01T00:00:00Z